Asceniv™ (immune globulin intravenous, human – slra) – New drug approval
April 1, 2019 - ADMA Biologics announced the FDA approval of Asceniv (immune globulin intravenous, human – slra), for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years of age).
Download PDF
